Oslo University Hospital

News and Video Search Results

News coverage

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

GlobeNewswire 17 May 2024

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”)..

Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
GlobeNewswire 25 Apr 2024
Does Using Your Brain More At Work Help Ward Off Thinking, Memory Problems?
Eurasia Review 18 Apr 2024
Ultimovacs – Invitation to Business Update on April 17, 2024
GlobeNewswire 09 Apr 2024
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire 04 Apr 2024

0 shares 1 views

You might like

Oslo University Hospital media coverage

Building A Decent Gaza – Analysis

Eurasia Review 28 Mar 2024

By Daniel Pipes

**Netanyahu's Plan**

On Feb. 22, 2024, Israel's Prime Minister Benjamin Netanyahu presented..

Nordea's Annual General Meeting 2024 and decisions of the statutory Board meeting
EQS Group 21 Mar 2024
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
GlobeNewswire 07 Mar 2024
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
GlobeNewswire 02 Mar 2024
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
GlobeNewswire 19 Feb 2024

Advertisement

More coverage

National Security Multi-Mission Vessel (NSMV) Program Achieves Milestone with Steel Cutting of Fifth Ship

Accesswire 09 Feb 2024

*NSMV V to be delivered to California State University Maritime Academy in 2026*

*PHILADELPHIA, PA / ACCESSWIRE /..

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
GlobeNewswire 05 Feb 2024
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
GlobeNewswire 16 Jan 2024
Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
EQS Group 08 Jan 2024
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
GlobeNewswire 18 Dec 2023